Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
26 studies found for:    Open Studies | "Inflammatory Breast Neoplasms"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Inflammatory Breast Neoplasms"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
Conditions: HER2/Neu Negative;   Recurrent Inflammatory Breast Carcinoma;   Stage IV Breast Cancer;   Stage IV Inflammatory Breast Carcinoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
2 Recruiting Case-Control Study of Inflammatory Breast Cancer in North Africa
Condition: Inflammatory Breast Cancer
3 Recruiting Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer
Condition: Inflammatory Breast Cancer
Interventions: Biological: Bevacizumab;   Drug: Cyclophosphamide;   Drug: epirubicin hydrochloride;   Drug: fluorouracil;   Drug: Docetaxel;   Biological: Trastuzumab
4 Recruiting A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Conditions: Inflammatory Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions: Drug: Eribulin;   Drug: Adriamycin;   Drug: Cyclophosphamide
5 Not yet recruiting Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Condition: Inflammatory Breast Cancer (IBC).
Interventions: Drug: Ruxolitinib;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide
6 Recruiting Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
Condition: Inflammatory Breast Carcinoma
Interventions: Drug: 89Zr-bevacizumab;   Procedure: FDG-PET/CT;   Procedure: MRI scan;   Procedure: Tumor biopsies
7 Recruiting Olaparib and Radiotherapy in Inoperable Breast Cancer
Conditions: Locally Advanced Malignant Neoplasm;   Inflammatory Breast Carcinoma;   Triple-Negative Invasive Breast Carcinoma
Interventions: Radiation: radiotherapy;   Drug: olaparib
8 Recruiting Inflammatory Breast Cancer (IBC) Registry
Condition: Breast Cancer
Interventions: Other: Interview;   Procedure: Blood and Tissue Collection
9 Unknown  Dose-escalation Study of Oral CX-4945
Conditions: Advanced Solid Tumors;   Breast Cancer;   Inflammatory Breast Cancer;   Castleman's Disease;   Multiple Myeloma
Intervention: Drug: CX-4945 oral formulation
10 Recruiting A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC)
Condition: Malignant Neoplasm of Breast
Interventions: Procedure: Breast Core Biopsy;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Panitumumab;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Procedure: Mammogram;   Procedure: Ultrasound;   Other: Follow Up
11 Recruiting MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC)
Condition: Breast Cancer
Interventions: Drug: MK-3475;   Behavioral: Follow Up/Phone Call
12 Recruiting Nintedanib For HER2-negative Metastatic Inflammatory Breast Cancer (MIBC)
Condition: Breast Cancer
Interventions: Drug: BIBF 1120;   Behavioral: Phone Call
13 Recruiting MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer
Condition: Breast Cancer
14 Recruiting Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response to Neoadjuvant Chemotherapy
Conditions: Invasive Ductal Breast Cancer;   Tubular Breast Cancer;   Mucinous Breast Cancer;   Inflammatory Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Cisplatin;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: 5-fluoruracil
15 Not yet recruiting Denosumab as an add-on Neoadjuvant Treatment (GeparX)
Conditions: Breast Cancer Female NOS;   Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Invasive Ductal Breast Cancer;   HER2 Positive Breast Cancer;   Inflammatory Breast Cancer;   Tubular Breast Cancer Stage III
Interventions: Drug: Denosumab;   Drug: nab-Paclitaxel;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Carboplatin;   Drug: Trastuzumab;   Drug: Pertuzumab
16 Recruiting Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive Breast Cancer Patients
Conditions: Tubular Breast Cancer;   Mucinous Breast Cancer;   Invasive Ductal Breast Cancer;   Inflammatory Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Cisplatin;   Drug: Gonadotropin-releasing hormone agonist;   Drug: Letrozole
17 Recruiting A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
Conditions: Tubular Breast Cancer Stage II;   Tubular Breast Cancer Stage III;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   HER2 Positive Breast Cancer;   Inflammatory Breast Cancer
Interventions: Drug: non-pegylated liposomal doxorubicin;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Pertuzumab;   Drug: Trastuzumab;   Drug: Ferric carboxymaltose
18 Recruiting Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
Conditions: Inflammatory Breast Cancer;   Stage IIA Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer;   Stage IIB Breast Cancer;   Estrogen Receptor Negative;   Progesterone Receptor Negative;   HER2/Neu Negative
Interventions: Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: laboratory biomarker analysis
19 Recruiting Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
Conditions: HER2-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Breast Adenocarcinoma;   Inflammatory Breast Carcinoma
Interventions: Biological: pertuzumab;   Biological: trastuzumab;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: laboratory biomarker analysis
20 Unknown  "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"
Conditions: Infiltrating Duct and Lobular Carcinoma In Situ;   Invasive Lobular Breast Carcinoma;   Inflammatory Breast Carcinoma
Intervention: Drug: Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Indicates status has not been verified in more than two years